Drugs / 68GA-DOTA-dPNE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06411678 | May 2024 → Dec 2025 overdue | breast cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06844110 | Mar → Dec 2025 overdue | virus associated tumor | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68GA-DOTA-dPNE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06411678 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-DOTA-dPNE PET/CT imaging” NCT06844110 ↗ |
| Route | Intravenous | “Each patient receive a single intravenous injection of 68GA-DOTA-dPNE 0.5-0.6 mci/kg” NCT06411678 ↗ |